✦ LIBER ✦

Review of Pulmonary Hemorrhage (PH) in Non–Small-Cell Lung Cancer (NSCLC) Subjects Receiving Bevacizumab and Cisplatin plus Gemcitabine on Protocol BO17704

✍ Scribed by F. LaFleur; J. Skillings; V. Hirsh; J. Bennouna; H.-P. Kuo; B. Szima; M. Gottfried; A. Kunitsyn; J.M. Trigo; G.-C. Chang; J. Cosaert; M. Reck

Book ID: 114412053
Publisher: CIG Media Group, LP.
Year: 2007
Tongue: English
Weight: 450 KB
Volume: 8
Category: Article
ISSN: 1525-7304
DOI: 10.1016/s1525-7304(11)70812-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6526 POSTER Review of pulmonary haemorrh

6526 POSTER Review of pulmonary haemorrhage (PH) in non-small cell lung cancer (NSCLC) subjects receiving bevacizumab and cisplatin plus gemcitabine on protocol BO17704

✍ Hirsh, V.; Bennouna, J.; Kuo, H.; Szima, B.; Gottfried, M.; Kunitsyn, A.; Trigo, 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Safety of Bevacizumab Treatment in Non–S

Safety of Bevacizumab Treatment in Non–Small-Cell Lung Cancer (NSCLC) Subjects Receiving Full-Dose Anticoagulation (FDAC) Treated on Protocol BO17704

✍ J. Skillings; F. LaFleur; N. Leighl; J. Bennouna; H.-P. Kuo; B. Szima; M. Gottfr 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 450 KB

6610 POSTER Safety of bevacizumab treatm

6610 POSTER Safety of bevacizumab treatment in non-small cell lung cancer (NSCLC) subjects receiving full-dose anti-coagulation (FDAC) treated on protocol BO17704

✍ Leighl, N.; Bennouna, J.; Kuo, H.; Szima, B.; Gottfried, M.; Kunitsyn, A.; Trigo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

6509 ORAL Management of hypertension (HT

6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704

✍ Bennouna, J.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

6503 ORAL Efficacy and safety results fr

6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

✍ Manegold, C.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

PCN14 AN INDIRECT COMPARISON OF THE EFFI

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

✍ S Walzer; J de Castro Carpeño; A Vergnenegre; C Chouaid; D Heigener; HG Bischoff 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB